Efavirenz plasma concentrations did not predict cessation of therapy due to neuropsychiatric symptoms in a large randomized trial.

Tim R H Read; Dianne L Carey; Patrick Mallon; Anne Mijch; Ruth Goodall; Fleur Hudson; Handan C Wand; Sean Emery

Efavirenz plasma concentrations did not predict cessation of therapy due to neuropsychiatric symptoms in a large randomized trial.

Tim R H Read, Dianne L Carey, Patrick Mallon, Anne Mijch, Ruth Goodall, Fleur Hudson, Handan C Wand, Sean Emery

Research output: Contribution to journal › Article › Research › peer-review

Abstract

To assess whether trial participants who ceased efavirenz (EFV) because of neuropsychiatric events had elevated plasma concentrations, we performed a retrospective case-control study. EFV levels were measured by high-performance liquid chromatography in stored plasma from 35 cases and 75 matched controls. All had taken EFV for at least 4 weeks. Median EFV concentrations did not differ (P = 0.77). Measurement of EFV levels in plasma collected at variable times after the last dose did not predict central nervous system intolerance.

Original language	English
Pages (from-to)	2222-2223
Number of pages	2
Journal	AIDS
Volume	23
Issue number	16
Publication status	Published - 23 Oct 2009

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{564a78ab39744afab2ff46990ed69f76,

title = "Efavirenz plasma concentrations did not predict cessation of therapy due to neuropsychiatric symptoms in a large randomized trial.",

abstract = "To assess whether trial participants who ceased efavirenz (EFV) because of neuropsychiatric events had elevated plasma concentrations, we performed a retrospective case-control study. EFV levels were measured by high-performance liquid chromatography in stored plasma from 35 cases and 75 matched controls. All had taken EFV for at least 4 weeks. Median EFV concentrations did not differ (P = 0.77). Measurement of EFV levels in plasma collected at variable times after the last dose did not predict central nervous system intolerance.",

author = "Read, {Tim R H} and Carey, {Dianne L} and Patrick Mallon and Anne Mijch and Ruth Goodall and Fleur Hudson and Wand, {Handan C} and Sean Emery",

year = "2009",

month = oct,

day = "23",

language = "English",

volume = "23",

pages = "2222--2223",

journal = "AIDS",

issn = "0269-9370",

publisher = "Lippincott Williams & Wilkins",

number = "16",

}

TY - JOUR

T1 - Efavirenz plasma concentrations did not predict cessation of therapy due to neuropsychiatric symptoms in a large randomized trial.

AU - Read, Tim R H

AU - Carey, Dianne L

AU - Mallon, Patrick

AU - Mijch, Anne

AU - Goodall, Ruth

AU - Hudson, Fleur

AU - Wand, Handan C

AU - Emery, Sean

PY - 2009/10/23

Y1 - 2009/10/23

N2 - To assess whether trial participants who ceased efavirenz (EFV) because of neuropsychiatric events had elevated plasma concentrations, we performed a retrospective case-control study. EFV levels were measured by high-performance liquid chromatography in stored plasma from 35 cases and 75 matched controls. All had taken EFV for at least 4 weeks. Median EFV concentrations did not differ (P = 0.77). Measurement of EFV levels in plasma collected at variable times after the last dose did not predict central nervous system intolerance.

AB - To assess whether trial participants who ceased efavirenz (EFV) because of neuropsychiatric events had elevated plasma concentrations, we performed a retrospective case-control study. EFV levels were measured by high-performance liquid chromatography in stored plasma from 35 cases and 75 matched controls. All had taken EFV for at least 4 weeks. Median EFV concentrations did not differ (P = 0.77). Measurement of EFV levels in plasma collected at variable times after the last dose did not predict central nervous system intolerance.

UR - http://www.scopus.com/inward/record.url?scp=79952115077&partnerID=8YFLogxK

M3 - Article

C2 - 19773634

AN - SCOPUS:79952115077

SN - 0269-9370

VL - 23

SP - 2222

EP - 2223

JO - AIDS

JF - AIDS

IS - 16

ER -

Efavirenz plasma concentrations did not predict cessation of therapy due to neuropsychiatric symptoms in a large randomized trial.

Abstract

UN SDGs

Other files and links

Cite this